Recent advances in the pharmacology of gastrointestinal prokinetics

Pharmacological Research

Volumn 33, Issue 4-5, 1996, Pages 217-226

  Tonini, Marcello ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

5 HT3 receptor antagonists; 5 HT4 receptor agonists; Dopamine D2 receptor antagonists; Gastrointestinal prokinetics; Inhibitors of nitric oxide synthase; Motilides

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; 1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 [2 (METHANESULFONAMIDO)ETHYL] 4 PIPERIDINYL] 1 PROPANONE; 4 AMINO 5 CHLORO 2 METHOXY N (3 PYRROLIZIDINYLMETHYL)BENZAMIDE; BENZAMIDE; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; GASTROINTESTINAL AGENT; GRANISETRON; LINTOPRIDE; METOCLOPRAMIDE; MOSAPRIDE CITRATE; NITRIC OXIDE SYNTHASE INHIBITOR; ONDANSETRON; RENZAPRIDE; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; TROPISETRON; UNCLASSIFIED DRUG; ZACOPRIDE;

ABDOMINAL DISCOMFORT; CLINICAL TRIAL; DIARRHEA; DRUG TARGETING; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; INTESTINE CONTRACTION; INTESTINE PSEUDOOBSTRUCTION; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH PARESIS; UPPER GASTROINTESTINAL TRACT; VOMITING;

EID: 0030130549     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0030     Document Type: Article

References (126)

1. 1. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone. Drugs 1982; 24: 360-400.
2. 2. Schulze-Delrieu K. Metoclopramide. Gastroenterology 1979; 77: 768-79.
3. 3. MacDonald TM. Metoclopramide, domperidone and dopamine in man: actions and interactions. Eur J Clin Pharmacol 1991; 40: 225-30.
4. 2) peripheral dopamine receptors by substituted benzamides. In: Rotrosen J, Stanley M, eds. The benzamides: pharmacology, neurobiology and clinical aspects. New York: Raven Press, 1982: 97-108.
5. 2 receptors. Gastroenterology 1984; 86: 1299.
6. 6. Nagahata Y, Azumi Y, Kawakita N, Saitoh Y. Inhibitory effect of dopamine on gastric motility in rats. Scand J Gastroenterol 1955; 30: 880-5.
7. 7. Holzbauer M, Sharman DF. The distribution of cathecolamines in vertebrates. In: Blaschko H, Muscholl E, eds. Handbook of experimental pharmacology, Vol. 33. New York: Springer Verlag, 1972: 110-85.
8. 8. Orloff LA, Orloff MS, Bunnet NW, Walsh JH. Dopamine and norepinephrine in the alimentary tract changes after chemical sympathectomy and surgical vagotomy. Life Sci 1985; 36: 1625-31.
9. 9. Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG. Presynaptic, ganglionic, and gastrointestinal dopamine receptors in the periphery. Pharmacol Rev 1985; 37: 165-216.
10. 10. Kilbinger H, Weihrauch TR. Drugs increasing gastrointestinal motility. Pharmacology 1982; 21: 61-72.
11. 11. Takahashi T, Kurosawa S, Wiley JW, Owyang C. Mechanism for the gastrokinetic action of domperidone. In vitro studies in guinea pigs. Gastroenterology 1991; 101: 703-10.
12. 12. Sanger GJ. Effects of metoclopramide and domperidone on cholinergically mediated contractions of human isolated stomach muscle. J Pharm Pharmacol 1985; 37: 661-4.
13. 13. Kilbinger H, Kruel R, Pfeuffer-Friederich I, Wessler I. The effects of metoclopramide on acetylcholine release and on smooth muscle response in the isolated guinea-pig ileum. Naunyn-Schmiedeberg's Arch Pharmacol 1982; 319: 231-8.
14. 14. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC. Metoclopramide - an updated review of its pharmacological properties and clinical use. Drugs 1983; 25: 451-94.
15. 15. Craig DA, Clarke DE. Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine4 receptor. J Pharmacol Exp Ther 1990; 252: 1378-86.
16. 4 receptor: a place in the sun. Trends Pharmacol Sci 1992; 13: 141-5.
17. 4 receptors and gastrointestinal prokinetic action. Pharmacol Res 1991; 24: 5-14.
18. 18. Costall B, Naylor RJ. 5-hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol 1990; 25: 769-87.
19. 3 receptor antagonist without gastroprokinetic activity. J Pharmacol Exp Ther 1990; 254: 350-5.
20. 20. Gullikson GW, Loeffler RF, Viriña MA. Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs. J Pharmacol Exp Ther 1991; 258: 103-10.
21. 21. Briejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 631-51.
22. 22. Tonini M, De Ponti F. Serotonin modulation of gastrointestinal motility. In: Gaginella TS, Galligan JJ, eds. Serotonin and gastrointestinal function. Boca Raton, FL: CRC Press, 1995: 53-84.
23. 3 receptor antagonists. In: Fozard JR, Saxena PR, eds. Serotonin: molecular biology, receptors and functional effects. Basel: Birkhäuser Verlag, 1991: 381-8.
24. 3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35: 477-80.
25. 4 receptor antagonist. J Gastrointest Motil 1993; 5: 192.
26. 4 receptor mediated stimulation of gastric emptying in rats. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 351: 589-95.
27. 27. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993; 118: 407-13.
28. 3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. Eur J Cancer 1993; 29: 22-9.
29. 3 antagonist action in the control of emesis. Pharm-acol Res 1995; 31: 257-60.
30. 30. Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988; 9: 334-41.
31. 31. Kanaizumi T, Nakano H, Matsuy Y, Ishikawa H, Shimizu R, Park S, Kuriya N. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41: 335-7.
32. 4 receptor agonist in the gut. Neurogastroenterol Motil 1994; 6: 197-204.
33. 4 receptor mechanism. J Pharmacol Exp Ther 1993; 264: 240-8.
34. 4 receptors. Eur J Pharmacol 1991; 205: 203-8.
35. 35. Tonini M, Galligan JJ, North RA. Effects of cisapride on cholinergic neurotransmission and propulsive motility in the guinea pig ileum. Gastroenterology 1989; 96: 1257-64.
36. 4 receptor activation. Br J Pharmacol 1991; 102: 563-4.
37. 4 receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 351: 229-36.
38. 38. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116-52.
39. 39. Tytgat GNJ (ed.). Management of gastrointestinal motility disorders. In: Gastro-oesophageal reflux and gastric stasis. Pathophysiology, diagnosis and therapy. Auckland: Adis International, 1991: 111-44.
40. 40. Tonini M, Ciccocioppo R, Onori L. Prokinetic drugs: a new approach to the treatment of functional disorders of the large bowel. Riv It Colonproctol 1992; 11: 172-80.
41. 4 receptors and potential therapeutic implications. Drugs Future 1991; 16: 1011-26.
42. 4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons. Am J Physiol 1994; 266: G230-8.
43. 43. Rizzi CA, Coccini T, Onori L, Manzo L, Tonini M. Benzimidazolone derivatives: a new class of 5-hydroxytryptamine4 receptor agonists with prokinetic and acetylcholine releasing properties in the guinea pig ileum. J Pharmacol Exp Ther 1992; 261: 412-9.
44. 44. Tonini M, Candura SM, Onori L, Coccini T, Manzo L, Rizzi CA. 5-hydroxytryptamine4 receptor agonists facilitate cholinergic transmission in the circular muscle of guinea pig ileum: antagonism by tropisetron and DAU 6285. Life Sci 1992; 50: 173-8.
45. 4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn-Schmiedeberg's Arch Pharmacol 1993; 347: 137-40.
46. 4 agonism. Pharmacol Res 1990; 22: 453.
47. 47. Rizzi CA, Sagrada A, Schiavone A, Schiantarelli P, Cesana R, Schiavi GB, Ladinsky H, Donetti A. Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 349: 338-5.
48. 4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br J Pharmacol 1995; 115: 1387-92.
49. 4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. J Med Chem 1995; 38: 2331-8.
50. 50. Talley NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1992; 6: 273-89.
51. 51. Sanger G. Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924. Br J Pharmacol 1987; 91: 77-87.
52. 52. Blackshaw LA, Nisyrios V, Dent J. Pathway of serotonin (5-HT) induced reduction of lower esophageal sphincter pressure in the ferret. Gastroenterology 1993; 104: A478.
53. 53. Delvaux M, Maisin JM, Arany Y, Atlan P, Cabanis MJ, Canal M, Frexinos J. Effect of the 5HT-3 antagonist/5HT-4 agonist lintopride on esophageal motility in healthy volunteers. Manometric study. Gastroenterology 1993; 104: A496.
54. 3-receptor antagonist, on perception of gastric distension and gastric compliance in healthy man. Gastroenterology 1993; 104: A603.
55. 55. Wilmer A, Tack J, Coremans G, Janssens J, Peeters T, Vantrappen G. 5-hydroxytryptamine-3 receptors are involved in the initiation of gastric phase-3 motor activity in humans. Gastroenterology 1993; 105: 773-80.
56. 56. De Boer WA, Tytgat GNJ. Review article: drug therapy for reflux oesophagitis. Aliment Pharmacol Ther 1994; 8: 147-57.
57. 57. Tytgat GNJ. The clinical use of cisapride in gastrooesophageal reflux disease, with particular focus in long-term treatment aspects. Scand J Gastroenterol 1995; 30 (Suppl. 211): 39-43.
58. 58. Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992; 33: 397-401.
59. 59. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 1886-99.
60. 60. Pilot MA, Ritchie HD, Thompson H, Zara GP. Alterations in gastrointestinal motility associated with erythromycin. Br J Pharmacol 1984; 81: 168.
61. 61. Otterson MF, Sarna SK. Gastrointestinal motor effects of erythromycin. Am J Physiol 1990; 259: 355-63.
62. 62. Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol 1984; 247: 688-94.
63. 63. Tomomasa T, Kuroume T, Arai H, Wakabayashi K, Itoh Z. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 1986; 31: 157-61.
64. 64. Tack J, Janssens J, Vantrappen G, Peeters T, Annese V, Depoortere I, Muls E, Bouillon R. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology 1992; 103: 72-9.
65. 65. Kawamura O, Sekiguchi T, Kusano M, Nishioka T, Itoh Z. Effect of erythromycin on interdigestive gastrointestinal contractile activity and plasma motilin concentration in humans. Dig Dis Sci 1993; 38: 870-6.
66. 66. Bruley des Varannes S, Parys V, Ropert A, Chayvialle JA, Rozé C, Galmiche JP. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 1995; 109: 32-9.
67. 67. Zara GP, Qin XY, Pilot MA, Thompson H, Maskell J. Response of the human gastrointestinal tract to erythromycin. J Gastrointest Motil 1991; 3: 26-31.
68. 68. Sarna SK, Soergel KH, Koch TR, Stone JE, Wood CM, Ryan RP, Arndorfer RC, Cavanaugh JH, Nellans HN, Lee MB. Gastrointestinal motor effects of erythromycin in humans. Gastroenterology 1991; 101: 1488-96.
69. 69. Landry C, Vidon N, Sogni P, Nepveux P, Chaumeil JP, Chauvin JP, Couturier D, Chaussade S. Effects of iv erythromycin (ERY) on gastric emptying, duodenocaecal transit time, gastric-and bilio-pancreatic secretion during enteral nutrition in healthy volunteers. Neurogastroenterol Motil 1994; 6: 146.
70. 70. Annese V, Janssens J, Vantrappen G, Tack J, Peeters TL, Willemse P, Van Cutsem E. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology 1992; 102: 823-8.
71. 71. Fraser R, Shearer T, Fuller J, Horowitz M, Dent J. Intravenous erythromycin overcomes small intestinal feedback on antral, pyloric, and duodenal motility. Gastroenterology 1992; 103: 114-19.
72. 72. Christofides ND, Long RG, Filzpatrick ML, McGregor GP, Bloom SR. Effect of motilin on the gastric emptying of glucose and fat in humans. Gastroenterology 1981; 80: 456-60.
73. 73. Schmid R, Schusdziarra V, Allescher HD, Bofilias I, Bullermann G, Classen M. Effect of motilin on gastric emptying in patients with diabetic gastroparesis. Diabetes Care 1991; 14: 65-8.
74. 74. Peeters TL, Muls E, Janssens J, Urbain JL, Bex M, Van Cutsem E, Depoortere I, De Roo M, Vantrappen G, Bouillon R. Effect of motilin on gastric emptying in patients wilh diabetic gastroparesis. Gastroenterology 1992; 102: 97-101.
75. 75. Kondo K, Torii T, Omura S, Itoh Z. Erythromycin and its derivatives with motilin-like biological activities inhibit the specific binding of 125 I-motilin to duodenal muscle. Biochem Biophys Res Commun 1988; 150: 877-82.
76. 76. Peeters T, Mattijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol 1989; 257: G470-4.
77. 77. You CH, Chey WY, Lee KY. Studies on plasma motilin concentration and interdigestive motility of the duodenum in humans. Gastroenterology 1980; 79: 62-6.
78. 78. Sarna SK, Ryan RP, Brandon A. Erythromycin acts on presynaptic neurons to stimulate gastrointestinal motor activity. Gastroenterology 1991; 100: A490.
79. 79. Yoshida N, Mizumoto A, Iwanaga Y, Itoh Z. Effects of 5-hydroxytryptamine 3 antagonists on gastrointestinal motor activity in conscious dogs. J Pharmacol Exp Ther 1991; 256: 272-8.
80. 80. Ohtawa M, Mizumoto A, Hayashi N, Yanagida K, Itoh Z, Omura S. Mechanism of gastroprokinetic effect of EM523, an erythromycin derivative, in dogs. Gastroenterology 1993; 104: 1320-7.
81. 81. Shiba Y, Mizumoto A, InatomiN, Haga N. Yamamoto O, Itoh Z. Stimulatory mechanism of EM523-induced contractions in postprandial stomach of conscious dogs. Gastroenterology 1995; 109: 1513-21.
82. 82. Janssens J, Vantrappen G, Annese V, Peeters TL, Tijskens G, Rekoumis G. Effect of erythromycin on LES function and oesophageal body contractility. Gastroenterology 1990; 98: A64.
83. 83. Chaussade S, Michopoulos S, Sogni P, Guerre J, Couturier D. Motilin agonist erythromycin increases human lower esophageal sphincter pressure by stimulation of cholinergic nerves. Dig Dis Sci 1994; 39: 381-4.
84. 84. Hasler W, Heldsinger A, Soudah H, Owyang C. Erythromycin promotes colonic transit in humans; mediation via motilin receptors. Gastroenterology 1990; 98: A358.
85. 85. Jameson JS, Rogers J, Misiewicz JJ, Raimundo AH. Oral or intravenous erythromycin has no effect on human distal colon motility. Aliment Pharmacol Ther 1992; 6: 589-95.
86. 86. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990; 322: 1028-31.
87. 87. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993; 88: 203-7.
88. 88. Mozwecz H, Pavel D, Pitrak D, Orellana P, Schlesinger PK, Layden TJ. Erythromycin stearate as prokinetic agent in postvagotomy gastroparesis. Dig Dis Sci 1990; 7: 902-5.
89. 89. Stacher G, Peeters TL, Bergamn H, Wiesnagrotzki S, Schneider C, Granser-Vacariu GV, Gaupmann G, Kugi A. Erythromycin effects on gastric emptying, antral motility and plasma motilin and pancreatic polypeptide concentrations in anorexia nervosa. Gut 1993; 34: 166-72.
90. 90. Miller SM, O'Dorisio TM, Thomas FB, Mekhjian HS. Erythromycin exerts a prokinetic effect in patients with chronic idiopathic intestinal pseudo-obstruction. Gastroenterology 1990; 98: A375.
91. 91. Vassallo MJ, Camilleri M, Sullivan SN, Thomforde GM. Effects of erythromycin on gut transit in pseudo-obstruction due to hereditary coproporphyria. J Clin Gastroenterol 1992; 14: 255-9.
92. 92. Armstrong DN, Ballantyne GH, Modlin IM. Erythromycin for reflex ileus in Ogilvie's syndrome. Lancet 1991; 337: 378.
93. 93. Bonacini M, Quiason S, Reynolds M, Gaddis M, Pemberton B, Smith O. Effect of intravenous erythromycin on postoperative ileus. Am J Gastroenterol 1993; 88: 208-11.
94. 94. Kawamura O, Sekiguchi T, Itoh Z, Omura S. Effect of erythromycin derivative EM523 on human interdigestive gastrointestinal tract. Dig Dis Sci 1993; 38: 1026-31.
95. 95. Matsueda K, Yamato S, Shoda R, Katsuta E, Miwa J, Okada R, Naitoh H, Masaki N, Hayashi S, Shimojo E, Umeda N. Effect of motilide (EM523L) on colonic motility in patients with constipation. Gastroenterology 1993; 104: A549.
96. 96. Fiorucci S, Distrutti E, Bassotti G, Gerli R, Chiucchiù S, Betti C, Santucci L, Morelli A. Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastroenterol 1994; 29: 807-13.
97. 97. Staiano A, Del Giudice E, Santoro L, Marsullo G, Marino A. Effect of cisapride on gastric emptying in children with progressive muscular dystrophy. Gastroenterology 1993; 104: A586.
98. 98. Tonini M, Crema A. Pharmacological treatment of colonic disorders. In: Caprilli R, Torsoli A, eds. Coloproctology, Basic knowledge for clinical practice. Rome: International University Press, 1990: 147-78.
99. 99. Krevsky B, Maurer AH, Malmud LS, Fisher RS. Cisapride accelerates colonic transit in constipated patients with colonic inertia. Am J Gastroenterol 1987; 84: 882-7.
100. 100. Staiano A, Cucchiara S, Andreotti MR, Minella R, Manzi G. Effect of cisapride on chronic idiopathic constipation in children. Dig Dis Sci 1991; 36: 733-6.
101. 101. Van Outryve M, Milo R, Toussaint J, Van Eeghem P. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991; 13: 49-57.
102. 102. Coremans G, Tack J, Vantrappen G, Coulie B. Cisapride decreases rectal compliance in patients with idiopathic megarectum. Gastroenterology 1989; 96: A100.
103. 103. Tollesson PO, Cassuto J, Rimback G, Faxen A, Bergman L, Mattsson E. Treatment of postoperative paralytic ileus with cisapride. Scand J Gastroenterol 1991; 26: 477-82.
104. 104. Tam FS-F, Hillier K, Buce KT. Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle. Br J Pharmacol 1994; 113: 143-50.
105. 4 receptors on the human stomach. J Gastrointest Motil 1991; 3: 199.
106. 106. Burleigh D, Trout SJ. Evidence against an acetylcholine releasing action of cisapride in the human colon. Br J Clin Pharmacol 1995; 20: 475-8.
107. 4 receptor in the secretory response of human small intestine to 5-HT. Br J Pharmacol 1993; 110: 927-8.
108. 108. Hansen MB. Serotonin - an intestinal secretagogue -receptor subtypes and intracellular mediators. Pharmacol Toxicol 1995; 77: 3-39.
109. 109. Delvaux M, Louvel D, Fioramonti J, Staumont G, Bueno L, Frexinos J. Effect of various doses of erythromycin on colonic myoelectrical activity in IBS patients. Neurogastroenterol Motil 1994; 6: 205-12.
110. 110. Bradette M, Poitras P, Boivin M. Effect of motilin and erythromycin on the motor activity of the human colon. J Gastrointest Motil 1993; 5: 247-51.
111. 111. Depoortere I, Peeters TL, Vantrappen G. Motilin receptors of the rabbit colon. Peptides 1991; 12: 89-94.
112. 112. Van Assche G, Thijs T, Depoortere I, Peeters TL. Excitatory effect of motilin on the isolated human colon. Gastroenterology 1995; 108: A703.
113. 113. Burnstock G. The nonadrenergic noncholinergic nervous system. Arch Int Pharmacodyn Ther 1986; 280: 1-15.
114. 114. Sanders KM, Ward SM. Nitric oxide as a mediator of nonadrenergic noncholinergic neurotransmission. Am J Physiol 1992; 262: 379-92.
115. 115. Stark ME, Szurszewski JH. Role of nitric oxide in gastrointestinal and hepatic function and disease. Gastroenterology 1992; 103: 1929-49.
116. 116. Knudsen MA, Tottrup A. A possible role of L-arginine-nitric oxide pathway in the modulation of cholinergic transmission in the guinea-pig taenia coli. Br J Pharmacol 1992; 107: 837-41.
117. 117. Hryhorenko LM, Woskowska Z, Fox-Threlkeld JET. Nitric oxide (NO) inhibits release of acetylcholine from nerves of isolated circular muscle of the canine ileum: relationship to motility and release of nitric oxide. J Pharmacol Exp Ther 1994; 271: 918-26.
118. 118. Bartho' L, Lefebvre R. Nitric oxide induces acetylcholine-mediated contractions in the guinea-pig small intestine. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 350: 582-4.
119. 119. Desai KM, Sessa WC, Vane JR. Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature 1991; 351: 477-9.
120. 120. Ciccocioppo R, Onori L, Messori E, Candura SM, Coccini T, Tonini M. Role of nitric oxide-dependent and -independent mechanisms in peristalsis and accommodation in the rabbit distal colon. J Pharmacol Exp Ther 1994; 270: 929-37.
121. 121. Waterman SA, Costa M, Tonini M. Accommodation mediated by enteric inhibitory reflexes in the isolated guinea-pig small intestine. J Physiol 1994; 474: 539-46.
122. 122. Waterman SA, Costa M. The role of enteric inhibitory motorneurons in peristalsis in the isolated guinea-pig small intestine. J Physiol 1994; 477: 459-68.
123. 123. Yamato S, Spechler SJ, Goyal RK. Role of nitric oxide in esophageal peristalsis in the opossum. Gastroenterology 1992; 103: 197-204.
124. 124. Orihata M, Sarna SK. Inhibition of nitric oxide synthase delays gastric emptying of solid meals. J Pharmacol Exp Ther 1994; 271: 660-70.
125. 125. Konturek JW, Fischer H, Gromotka PM, Stoll R, Domschke W. Endogenous nitric oxide (NO) in the regulation of gastric motor activity in humans. Gastroenterology 1995; 108: A630.
126. 126. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.